TrialPath
← Back to searchRecruiting

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

NCT07174622 · Medtronic Vascular
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data
About this study
The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.
Eligibility criteria
Inclusion Criteria: * Enrolled in a Medicare plan * Diagnosis of uncontrolled hypertension * On a stable regimen of antihypertensive therapy Exclusion Criteria: * A prior RDN procedure * Diagnosis of secondary hypertension * Any condition for which RDN is contraindicated
Study design
Enrollment target: 1000 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-10-28
Estimated completion: 2029-06
Last updated: 2026-02-25
Interventions
Device: Renal Denervation (Symplicity Spyral™)
Primary outcomes
  • Change in Office Systolic Blood Pressure (OSBP) (2 years)
Sponsor
Medtronic Vascular · industry
Contacts & investigators
ContactKael Wherry, PhD, MS · contact · kael.wherry@medtronic.com · 612-229-0714
InvestigatorEric A Secemsky, MD, MSc · principal_investigator, Beth Israel Deaconess Medical Center
All locations (1)
Beth Israel Deaconess Medical CenterRecruiting
Boston, Massachusetts, United States
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation · TrialPath